NCT00711789UNKNOWNanonymous

A Pilot Crossover Randomised Controlled Trial of Angiotensin II in Critically Ill Patients With Severe Sepsis and Acute Renal Failure

Sponsor

Source record

Austin Health

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Angiotensin II, Saline placebo

Indication / condition

AI-normalized

Acute Renal Failure

Intervention

Source record

Angiotensin II, Saline placebo

Related intelligence directories

Indication directory: Acute Renal Failure Modality directory: small molecule Target directory: Angiotensin II

Source & freshness

Source record

NCT ID

NCT00711789

Original source

ClinicalTrials.gov

Source last updated

Jun 23, 2011

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT00711789

Title

A Pilot Crossover Randomised Controlled Trial of Angiotensin II in Critically Ill Patients With Severe Sepsis and Acute Renal Failure

Sponsor

Austin Health

Status

UNKNOWN

Phase

PHASE2

Condition raw

Acute Renal Failure, Sepsis, Septic Shock

Condition normalized

Acute Renal Failure, Sepsis, Septic Shock

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Angiotensin II, Saline placebo

Target normalized

Angiotensin II, Saline placebo

Interventions

Angiotensin II, Saline placebo

Public preview

Source record

It will also help determine the feasibility of conducting a definitive and adequately powered randomised controlled trial of angiotensin II in such patients that would assess mortality and need for renal replacement therapy as endpoints.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Pilot Crossover Randomised Controlled Trial of Angiotensin II in Critically Ill Patients With Severe Sepsis and Acute Renal Failure

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 18, 2026

NCT ID

NCT00711789

Status

UNKNOWN

Phase

PHASE2

Sponsor

Austin Health

Executive brief

Investment-Ready Snapshot

The purpose of this study is to determine the effect of a systemic infusion of angiotensin II on haemodynamics and urine output in critically ill patients with severe sepsis/septic shock and acute renal failure. It will also help determine the feasibility of conducting a definitive and adequately powered randomised controlled trial of angiotensin II in such patients that would assess mortality and need for renal replacement therapy as endpoints.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJun 23, 2011

Internal syncJun 18, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00711789

Indication

Acute Renal Failure

Modality

small molecule

Target

Angiotensin II, Saline placebo

Intervention

Angiotensin II, Saline placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.